Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M93,727Revenue $M25,711Net Margin (%)3.8Z-Score2.5
Enterprise Value $M97,724EPS $2.0Operating Margin %7.1F-Score4
P/E(ttm))98.4Cash Flow Per Share $0Pre-tax Margin (%)4.1Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %9.9Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %-9.5Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-29.8ROA % (ttm)1.8Higher Current Ratio y-yN
Dividend Yield %3.8Insider Buy (3m)0ROE % (ttm)4.5Less Shares Outstanding y-yN
Payout Ratio %343Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNCharles Brandes 2014-09-30 Sold Out -0.35%$68.49 - $76.31
($73.2)
$ 74.211%Sold Out0
AZNJohn Hussman 2014-09-30 Reduce-0.29%$68.49 - $76.31
($73.2)
$ 74.211%Reduce -22.37%173,500
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 74.213%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 74.213%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 74.213%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 74.213%Sold Out0
AZNNWQ Managers 2014-06-30 Reduce-0.01%$62.45 - $81.09
($72.26)
$ 74.213%Reduce -24.55%64,475
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 74.2115%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 74.2115%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 74.2115%New holding, 95518 sh.95,518
AZNHOTCHKIS & WILEY 2014-03-31 Sold Out -0.93%$58.51 - $68.38
($64.41)
$ 74.2115%Sold Out0
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 74.2115%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 74.2137%Reduce -40.32%106,975
AZNHOTCHKIS & WILEY 2013-12-31 Reduce-0.3%$49.72 - $59.5
($54.28)
$ 74.2137%Reduce -24.9%3,689,214
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 74.2137%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 74.2148%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 74.2148%Reduce -81.87%68,000
AZNHOTCHKIS & WILEY 2013-06-30 Add0.68%$47.22 - $53.01
($50.92)
$ 74.2146%Add 131.18%4,944,742
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 74.2146%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 74.2146%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-09-3041,90000.02+3.71%
AZN George Soros 2014-09-30150,0000.010.08
AZN NWQ Managers 2014-09-3064,4750.010.05
AZN David Dreman 2014-09-30117,0030.010.68-0.7%
AZN John Hussman 2014-09-30173,5000.011.1-22.37%
AZN Charles Brandes 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$17343.41view

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
      A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 


      More From Other Websites
      U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs Nov 20 2014
      Neil Woodford invests £16m in brain cancer vaccine company Nov 19 2014
      The S&P failed to extend its 4-day winning streak following headlines out of the Fed Nov 19 2014
      AstraZeneca Targets More than $45B in Revenues in 2023 Nov 19 2014
      European shares erase gains ahead of Fed minutes Nov 19 2014
      Sanofi's case for experimental drugs in pipeline Nov 19 2014
      AstraZeneca launches and prices a €750,000,000 7 year bond issue Nov 19 2014
      FTSE 100 movers: Royal Mail dives after admitting parcels business remains challenging Nov 19 2014
      Global Oncology Market to hit $109 billion - Spotlight on Drug Life Cycle Management, M&A and... Nov 19 2014
      European shares edge lower ahead of Fed minutes Nov 19 2014
      Clovis Lung Cancer Update Swings Momentum to Rival, Slightly Nov 19 2014
      Market Overview: AstraZeneca boosted by broker comments Nov 19 2014
      European shares edge higher, Swiss index hits 7-year high Nov 19 2014
      Inovio-Roche End Deal for Development of Cancer Therapy Nov 18 2014
      AstraZeneca advances in London; pound rises as inflation ticks up Nov 18 2014
      Neil Woodford: there's a 50/50 chance Pfizer will come back for AstraZeneca Nov 18 2014
      AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
      Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies Nov 18 2014
      6:45 am AstraZeneca provides update on the company's progress Nov 18 2014
      Neil Woodford Praises AstraZeneca plc’s Prospects Nov 18 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK